Henry Meds sells GLP-1 weight care as a flat monthly price that bundles the visit, the prescribing, and the medication together, and for many of its plans that medication has been compounded rather than brand. The advertised number is real but incomplete. What you actually pay over time shifts with your dose tier, with the end of any introductory rate, and with whether you had insurance coverage you never checked. The flat price is the selling point, and it is also where the fine print lives.
What does the flat monthly fee actually buy?
The pitch is simple: one recurring charge, no insurance, medication shipped to the door. That model exists because it removes the parts of drug pricing people hate, the deductible math and the prior authorization waiting room. In its compounded GLP-1 programs, Henry Meds has generally folded the clinician visit, the prescription, and the medication into a single monthly figure. For a cash payer with no weight-management coverage, that predictability has genuine value.
The catch is that the headline price usually reflects a starting arrangement. GLP-1 dosing climbs over months, and pricing tiers often climb with it. The figure worth writing down is the maintenance-dose price, not the first-month price, because that is what the budget lives with once the medication is doing its job.
Is this brand medication or compounded medication?
This is the part most reviews skate past. A large share of low-cost telehealth GLP-1 pricing, Henry Meds included, has been built on compounded semaglutide or tirzepatide. Compounded drugs are prepared by a compounding pharmacy and are not FDA-approved products. They may contain the same active molecule as Wegovy or Zepbound, but they have not gone through the approval process, and the FDA has been explicit that compounded versions do not carry the same review as approved drugs, as its compounding questions and answers describe.
That distinction has real safety weight. A 2025 pharmacovigilance analysis of compounded GLP-1 reports in the FDA adverse event system found signals worth taking seriously, and a documented case series of dosing errors reported to a poison control center traced problems to patients measuring their own doses from multi-dose vials. Clinician guidance on compounded semaglutide stresses that the trade is regulatory assurance for access and price. None of that makes compounding illegitimate. It means the cheaper number carries a different risk profile, and that belongs in the comparison honestly.
How do the pricing routes compare?
| Route | What sets the number | Main limitation |
|---|---|---|
| Henry Meds flat monthly plan | Bundled visit and compounded medication, by dose tier | Often compounded, not an FDA-approved product |
| Other telehealth cash plans | Provider and pharmacy pricing | Same compounding question applies |
| Manufacturer self-pay (brand) | Fixed cash price set by the maker | Refill-timing and dose conditions |
| Covered insurance benefit | Formulary tier, deductible, coinsurance | Requires the plan to cover the category |
Is Henry Meds actually the cheapest option?
Not automatically. If a plan already covers anti-obesity medication, a covered brand can undercut any cash service once the deductible is met. If there is no coverage, the honest comparison is against other cash routes: brand self-pay programs from the manufacturers, and other supervised telehealth practices. Henry Meds sits inside a real named field that includes Ro, Hims and Hers, LillyDirect, and NovoCare, and it is one legitimate physician-supervised option rather than a category of its own.
Prices in this field move quickly, so the useful exercise is comparing the same thing across providers: same molecule, same maintenance dose, same total monthly cost after any promotion ends. Practices that publish flat pricing, including options such as Henry Meds weight loss alternatives, make that side-by-side easier because the number is stated up front rather than buried in a claims process. The point is to compare steady-state figures, not launch offers.
Where do the surprise costs come from?
Three places, mostly. First, dose escalation: a price that looked fine at a low starting dose can jump at the maintenance dose. Second, expiring promotions, where the first few months are discounted and the ongoing rate is higher. Third, and most overlooked, the cost is ongoing. Trial evidence is blunt about this. The STEP 1 extension found that participants regained much of their lost weight after stopping semaglutide, and the STEP 4 trial showed continued treatment was needed to hold the loss. A monthly price is really an indefinite price, and that changes the arithmetic.
Does the underlying medication work?
The active molecules are well studied. Semaglutide produced large, consistent weight loss across the STEP program, including as an adjunct to intensive behavioral therapy in STEP 3 and against an active comparator in the STEP 8 trial, and the drug class is a mainstay in guidance on drugs for type 2 diabetes. That evidence was generated with approved products. A compounded preparation may use the same molecule, but the trial data attaches to the approved drug, not to whatever a given pharmacy compounds. Worth keeping straight when a low price is framed as buying the same thing.
See also: Industrial Plastic Grinders: Key Considerations for Buyers
Key takeaways
- The advertised Henry Meds price is often a starting-dose, promotional figure; check the maintenance-dose price.
- Much of its low-cost GLP-1 care has been compounded, which is not FDA-approved and carries a different risk profile.
- People with weight-management coverage may pay less through a covered brand than through any cash plan.
- Because stopping the drug is linked to weight regain, the real cost is ongoing, not a single month.
See also: Cloud Gaming Explained
Frequently asked questions
Does the Henry Meds monthly price include the medication?
In its compounded programs, the flat monthly fee is generally built to cover the visit, the prescribing, and the medication together. That bundling is the whole appeal, but the number changes by dose tier and by whether promotional pricing has ended, so the steady-state figure matters more than the intro figure.
Is Henry Meds cheaper than getting Wegovy or Zepbound through insurance?
It depends entirely on coverage. Someone whose plan covers anti-obesity medication may pay less through a covered benefit than through any cash telehealth service. Someone with no coverage often finds flat cash pricing predictable, which is the situation the model is built for.
Is Henry Meds selling FDA-approved drugs?
Much of its GLP-1 offering has been compounded semaglutide or tirzepatide, which is prepared by a compounding pharmacy and is not an FDA-approved product. It may contain the same active molecule as the brand, but it has not been through the approval process behind the published trials.
Are there hidden costs beyond the advertised monthly price?
The common surprises are dose escalation moving you into a higher price tier, promotional pricing expiring after the first months, and the ongoing nature of the cost, since stopping the drug is associated with weight regain in trial data.
What should be checked before signing up?
Whether the medication is compounded or brand, what the price becomes at the maintenance dose rather than the starting dose, and whether an existing insurance plan already covers a brand version at lower cost.
